Abstract
Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk factors for the development of HCC. Currently, the treatment options are rather limited, and the prognosis for this malignancy is poor for most of these patients. RNA interference has emerged as an innovative technology for gene silencing and as a potential therapeutic for various diseases, including cancer. HCC has been widely chosen as a model system for the development of RNAi therapy due to the convenience and availability of effective delivery of RNA molecules into liver tissues. Targets for HCC treatment include HBV and HCV viruses, oncogenes, as well as cellular genes mediating angiogenesis, tumor growth and metastasis. Here, we summarized the progress of RNAi therapeutics in HCC treatment, relevant patents, potential challenges and prospects in the future.
Keywords: HCC, RNAi, Hepatocellular carcinoma, aflatoxin B1, Akt signaling, hepatocarcinogenesis, VEGFR, Drosha's cleavage, transcriptional gene silencing, RISC, TERT, IRES, DICER1, cadherin-17, STAT3, TGFBR, FoxM1B, CIAPIN1, metalloprotease, Transferrin, ALN-VSP02, SNALPs
Recent Patents on Anti-Cancer Drug Discovery
Title: RNA Interference as Therapeutics for Hepatocellular Carcinoma
Volume: 6 Issue: 1
Author(s): Chuanrui Xu, Susie A. Lee and Xin Chen
Affiliation:
Keywords: HCC, RNAi, Hepatocellular carcinoma, aflatoxin B1, Akt signaling, hepatocarcinogenesis, VEGFR, Drosha's cleavage, transcriptional gene silencing, RISC, TERT, IRES, DICER1, cadherin-17, STAT3, TGFBR, FoxM1B, CIAPIN1, metalloprotease, Transferrin, ALN-VSP02, SNALPs
Abstract: Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk factors for the development of HCC. Currently, the treatment options are rather limited, and the prognosis for this malignancy is poor for most of these patients. RNA interference has emerged as an innovative technology for gene silencing and as a potential therapeutic for various diseases, including cancer. HCC has been widely chosen as a model system for the development of RNAi therapy due to the convenience and availability of effective delivery of RNA molecules into liver tissues. Targets for HCC treatment include HBV and HCV viruses, oncogenes, as well as cellular genes mediating angiogenesis, tumor growth and metastasis. Here, we summarized the progress of RNAi therapeutics in HCC treatment, relevant patents, potential challenges and prospects in the future.
Export Options
About this article
Cite this article as:
Xu Chuanrui, A. Lee Susie and Chen Xin, RNA Interference as Therapeutics for Hepatocellular Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793980097
DOI https://dx.doi.org/10.2174/157489211793980097 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insights on the Mode of Action of Microcystins in Animal Cells - A Review
Mini-Reviews in Medicinal Chemistry SBRT for Liver Cancer
Current Cancer Therapy Reviews The Human OncoBiome Database: A Database of Cancer Microbiome Datasets
Current Bioinformatics Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma
Current Topics in Medicinal Chemistry Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Reviews on Recent Clinical Trials The Structure and Pharmacological Functions of Coumarins and Their Derivatives
Current Medicinal Chemistry Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Occurrence and Biological Properties of Sphingolipids - A Review
Current Nutrition & Food Science <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Steroidal Conjugates and Their Pharmacological Applications
Current Medicinal Chemistry Nucleosides with Modified Sugar Ring: Synthesis and Biological Activities
Current Organic Chemistry Meet Our Editorial Board Member
Current Protein & Peptide Science Brain MR Image Classification for Glioma Tumor detection using Deep Convolutional Neural Network Features
Current Medical Imaging Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma
Current Cancer Drug Targets